

RECEIVED

DEC 12 1998

PATENT EXTENSION
A/C PATENTS

RECEIVED

DEC 22 1998

PATENT EXTENSION
A/C PATENTS

Exhibit C

**Terminal Disclaimer
Related to U.S. Patent 5,712,155**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :
Craig A. Smith, Raymond G. Goodwin
and M. Patricia Beckman

Docket No.: 2501-E

Serial No.: 08/346,555

Examiner: D. Basham

Filed: November 29, 1994

Group Art Unit: 1800 ¹⁸¹²

For: DNA ENCODING TUMOR NECROSIS FACTORS - α AND - β RECEPTORS

Commissioner of Patents
and Trademarks
Washington, DC 20231

RECEIVED
JUL 25 1997
GROUP 1800

TERMINAL DISCLAIMER UNDER 37 CFR 1.321 (b)

Immunex Corporation, a corporation of Washington and having a principal place of business at 51 University Street, Seattle, Washington 98101, represents that it is the assignee of of application Serial No. 08/346,555, filed November 29, 1994 for "DNA Encoding Tumor Necrosis Factors- α and - β Receptors." The application was assigned to Immunex Corporation by virtue of the assignment recorded with the United States Patent and Trademark Office on October 13, 1989 at Reel 5158/Frame 0462 in the parent application Serial No. 07/421,417.

Immunex Corporation hereby disclaims the terminal part of any patent granted on this patent application, Serial No.08/346,555, that would extend beyond March 7, 2012 (the expiration date of U.S. Patent No. 5,395,760). Immunex Corporation also agrees that any patent granted on this application shall be enforceable only for and during such period that the legal title to the present application shall be the same as the legal title to United States Patent No. 5,395,760. This agreement by Immunex Corporation is to run with any patent granted on the present application and is to be binding upon the grantee, its successors and assigns.

In accordance with 37 CFR 3.73(b), Immunex Corporation hereby certifies that the evidentiary documents regarding the chain of title of patent application Serial No. 08/346,555 have been reviewed. In addition, Immunex Corporation hereby certifies that to the best of its knowledge and belief, title is in the assignee seeking to take the action herein.

IMMUNEX CORPORATION


Stephen L. Malaska
Director, Intellectual Property
Reg. No. 32,655